CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

01 апр 2024 05:00:00 Источник Nasdaq GlobeNewswire

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

15 фев 2024 13:07:00 Источник Nasdaq GlobeNewswire

Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial

15 фев 2024 13:02:00 Источник Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call

08 фев 2024 13:05:00 Источник Nasdaq GlobeNewswire

Corcept Appoints Roberto Vieira as President, Oncology

29 янв 2024 05:00:00 Источник Nasdaq GlobeNewswire

Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program

08 янв 2024 05:00:01 Источник Nasdaq GlobeNewswire

Court Finds Corcept Therapeutics’ Patents Not Infringed

02 янв 2024 05:00:00 Источник Nasdaq GlobeNewswire

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

01 ноя 2023 13:05:00 Источник Nasdaq GlobeNewswire

Corcept Appoints Monica Tellado as President, Emerging Markets

01 ноя 2023 05:00:00 Источник Nasdaq GlobeNewswire

Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)

26 окт 2023 13:05:00 Источник Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

25 окт 2023 13:05:00 Источник Nasdaq GlobeNewswire

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

02 авг 2023 13:05:01 Источник Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

26 июл 2023 13:05:00 Источник Nasdaq GlobeNewswire

Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)

17 июл 2023 13:05:00 Источник Nasdaq GlobeNewswire

Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer

27 июн 2023 05:00:00 Источник Nasdaq GlobeNewswire

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

03 май 2023 13:05:01 Источник Nasdaq GlobeNewswire

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

26 апр 2023 13:05:01 Источник Nasdaq GlobeNewswire

Corcept Therapeutics Announces Final Results of Tender Offer

05 апр 2023 13:05:00 Источник Nasdaq GlobeNewswire

Corcept Therapeutics Announces Preliminary Results of Tender Offer

03 апр 2023 05:00:01 Источник Nasdaq GlobeNewswire

Corcept Therapeutics Initiates CATALYST Clinical Trial

28 мар 2023 13:05:00 Источник Nasdaq GlobeNewswire